Citius Oncology, Inc. (CTOR)

Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $93.57 million. The enterprise value is $93.45 million.

Market Cap	93.57M
Enterprise Value	93.45M

Important Dates

The next estimated earnings date is Wednesday, February 11, 2026, after market close.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Citius Oncology has 88.28 million shares outstanding. The number of shares has increased by 7.66% in one year.

Current Share Class	88.28M
Shares Outstanding	88.28M
Shares Change (YoY)	+7.66%
Shares Change (QoQ)	+9.59%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	0.86%
Float	14.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	1.66
PB Ratio	1.97
P/TBV Ratio	2.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.56, with a Debt / Equity ratio of 0.08.

Current Ratio	0.56
Quick Ratio	0.08
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-107.89

Financial Efficiency

Return on equity (ROE) is -54.42% and return on invested capital (ROIC) is -29.82%.

Return on Equity (ROE)	-54.42%
Return on Assets (ROA)	-15.87%
Return on Invested Capital (ROIC)	-29.82%
Return on Capital Employed (ROCE)	-45.72%
Weighted Average Cost of Capital (WACC)	20.65%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Citius Oncology has paid $1.06 million in taxes.

Income Tax	1.06M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.67% in the last 52 weeks. The beta is 3.10, so Citius Oncology's price volatility has been higher than the market average.

Beta (5Y)	3.10
52-Week Price Change	-11.67%
50-Day Moving Average	1.15
200-Day Moving Average	1.59
Relative Strength Index (RSI)	43.68
Average Volume (20 Days)	246,029

Short Selling Information

The latest short interest is 1.20 million, so 1.36% of the outstanding shares have been sold short.

Short Interest	1.20M
Short Previous Month	983,877
Short % of Shares Out	1.36%
Short % of Float	8.28%
Short Ratio (days to cover)	2.33

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-23.52M
Pretax Income	-23.70M
Net Income	-24.76M
EBITDA	n/a
EBIT	-23.52M
Earnings Per Share (EPS)	-$0.34

Balance Sheet

The company has $3.92 million in cash and $3.80 million in debt, with a net cash position of $124,797 or $0.00 per share.

Cash & Cash Equivalents	3.92M
Total Debt	3.80M
Net Cash	124,797
Net Cash Per Share	$0.00
Equity (Book Value)	44.87M
Book Value Per Share	0.54
Working Capital	-21.95M

Cash Flow

Operating Cash Flow	-5.49M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.66%
Shareholder Yield	-7.66%
Earnings Yield	-26.46%
FCF Yield	n/a

Analyst Forecast

The average price target for Citius Oncology is $6.00, which is 466.04% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.00
Price Target Difference	466.04%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2